benign prostatic hyperplasia and glycosaminoglycan

Conditions: Prostatic Hyperplasia

Summary: lower urinary tract symptoms (luts) are one of the most common conditions in the urology clinic, affecting at least one in four men after 40 years of age. benign prostatic hyperplasia is the most common cause of luts. bladder dysfunction (hypersensitivity or detrusor overactivity) and bladder outlet obstruction are two main pathologies involved in the etiology of luts. in men aged 40-49, moderate and severe luts are reported as 26%, while this ratio is doubled in the age group of 70 years and older. clinically, bph is defined as an international symptom score of more than 8, a prostate volume of more than 30 ml, and a maximum flow rate of less than 15 ml / sec. alpha blockers are recommended as the first-line medical treatment according to european urology guidelines (eau guidelines 2018) for patients diagnosed with bph clinically. in recent years, many studies have been published on the relationship of urinary biomarkers with luts. nerve growth factor and brain derived neurotrophic factor have been shown to be closely related to neurogenic or non-neurogenic detrusor overactivity and significant improvements were observed after treatment.the relationship between urinary glycosaminoglycan and overactive bladder has been shown and it has been reported that the values have decreased after treatment.male patients with luts caused by bph often have symptoms of overactive bladder. however, as far as we know, there is no study in the literature about the meaning of urinary gag levels in this patient group. the aim of this study was to investigate the relationship between urinary glycosaminoglycan levels and patients who had benign prostatic hyperplasia with and without overactive bladder symptoms.

35 patients and 10 controls were planned to be included in the study. urine will be collected from patients before and after one month of medical treatment (alpha-blocker). after being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° c. at the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method. urine gag levels and pre and post treatment uroflowmetry, ipss, overactive bladder symptom score, bladder frequency volume chart, post void residual urine volume will be compared.

Eligibility criteria:
eligibility criteria 1. male patients presenting with lower urinary tract symptoms to urology outpatient clinic 2. according to the european association of urology guidelines: 1. international prostate symptom score\> 8 2. prostate volume\> 40 ml 3. q max \<15 ml /sn 3. patients who did not receive any treatment for lower urinary tract symptoms and applied for the first time 4. patients who have not undergone lower urinary tract surgery exclusion criteria 1. patients who had undergone medical and surgical treatment for lower urinary tract symptoms 2. patients with accompanying urethral stricture 3. patients with neurological diseases (parkinson's, multiple sclerosis etc ...) 4. patients with spinal cord trauma 5. patients with indication for surgical treatment at the time of initial admission (macroscopic hematuria, bladder stone, urinary retention, upper urinary tract dilatation)

Keywords: prostatic hyperplasia lower urinary tract symptoms medical treatment urine marker glycosaminoglycan